$9.06 Million in Sales Expected for Conatus Pharmaceuticals Inc (CNAT) This Quarter

Wall Street brokerages forecast that Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will announce $9.06 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Conatus Pharmaceuticals’ earnings. The lowest sales estimate is $4.88 million and the highest is $10.64 million. Conatus Pharmaceuticals reported sales of $10.01 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 9.5%. The company is expected to issue its next quarterly earnings report on Wednesday, August 1st.

According to Zacks, analysts expect that Conatus Pharmaceuticals will report full-year sales of $40.26 million for the current fiscal year, with estimates ranging from $34.25 million to $47.70 million. For the next fiscal year, analysts expect that the business will post sales of $55.77 million per share, with estimates ranging from $34.00 million to $85.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that that provide coverage for Conatus Pharmaceuticals.

Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its earnings results on Wednesday, May 2nd. The biotechnology company reported ($0.17) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.17). The firm had revenue of $9.74 million for the quarter, compared to the consensus estimate of $8.88 million. Conatus Pharmaceuticals had a negative net margin of 49.30% and a negative return on equity of 64.30%.

A number of equities research analysts have issued reports on the stock. ValuEngine cut shares of Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, April 6th. Oppenheimer assumed coverage on shares of Conatus Pharmaceuticals in a report on Thursday, March 1st. They set a “buy” rating and a $16.00 price target for the company. SunTrust Banks decreased their price target on shares of Conatus Pharmaceuticals to $4.30 and set a “buy” rating for the company in a report on Thursday, April 5th. HC Wainwright decreased their price target on shares of Conatus Pharmaceuticals from $17.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, April 5th. Finally, Zacks Investment Research upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, April 10th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $12.14.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CNAT. BlackRock Inc. lifted its stake in shares of Conatus Pharmaceuticals by 45.4% in the first quarter. BlackRock Inc. now owns 2,316,808 shares of the biotechnology company’s stock valued at $13,601,000 after buying an additional 723,413 shares during the period. MPM Asset Management LLC raised its position in Conatus Pharmaceuticals by 17.3% in the first quarter. MPM Asset Management LLC now owns 2,464,807 shares of the biotechnology company’s stock worth $14,468,000 after purchasing an additional 363,636 shares in the last quarter. American Century Companies Inc. acquired a new position in Conatus Pharmaceuticals in the first quarter worth about $643,000. Geode Capital Management LLC raised its position in Conatus Pharmaceuticals by 26.2% in the fourth quarter. Geode Capital Management LLC now owns 429,556 shares of the biotechnology company’s stock worth $1,983,000 after purchasing an additional 89,179 shares in the last quarter. Finally, Macquarie Group Ltd. raised its position in Conatus Pharmaceuticals by 116.8% in the fourth quarter. Macquarie Group Ltd. now owns 130,300 shares of the biotechnology company’s stock worth $602,000 after purchasing an additional 70,200 shares in the last quarter. Institutional investors and hedge funds own 40.56% of the company’s stock.

CNAT stock opened at $5.14 on Thursday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.41 and a quick ratio of 2.41. Conatus Pharmaceuticals has a 52-week low of $3.22 and a 52-week high of $7.95. The stock has a market cap of $133.18 million, a price-to-earnings ratio of -8.43 and a beta of 1.29.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Get a free copy of the Zacks research report on Conatus Pharmaceuticals (CNAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply